Boule Diagnostics AB (CHIX:BOULS) Piotroski F-Score: 5 (As of Jul. 14, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BOULS Boule Diagnostics AB CHIX:BOULS
47 GF Score
Price kr26.30
GF Value kr49.42
! 2 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Piotroski F-Score?

Boule Diagnostics AB CHIX:BOULS 47 Piotroski F-Score is 5 as of Jul. 14, 2026, which is at its 10-year median of 5.00. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Boule Diagnostics AB ranks better than 65.01% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Boule Diagnostics AB has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Boule Diagnostics AB's Piotroski F-Score or its related term are showing as below:

CHIX:BOULs' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Boule Diagnostics AB was 8. The lowest was 2. And the median was 5.

Boule Diagnostics AB  (CHIX:BOULs) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Boule Diagnostics AB Piotroski F-Score Related Terms


Boule Diagnostics AB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Piotroski F-Score Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 2.00 6.00 4.00 5.00

Boule Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 5.00 5.00 5.00

CHIX:BOULS vs ABT, SYK, MDT: Piotroski F-Score Comparison

For the Medical Devices subindustry, Boule Diagnostics AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boule Diagnostics AB Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Boule Diagnostics AB's Piotroski F-Score falls into.


CHIX:BOULS
47GF Score
Boule Diagnostics AB CHIX:BOULS
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -5.7 + 10.9 + 1.6 + -14.6 = kr-7.8 Mil.
Cash Flow from Operations was -2.7 + 1.8 + 9.6 + 11.7 = kr20.4 Mil.
Revenue was 129.4 + 127.2 + 120.2 + 101.6 = kr478.4 Mil.
Gross Profit was 50.1 + 52.4 + 57.7 + 42.2 = kr202.4 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(495 + 465.4 + 461.2 + 469.557 + 468.8) / 5 = kr471.9914 Mil.
Total Assets at the begining of this year (Mar25) was kr495.0 Mil.
Long-Term Debt & Capital Lease Obligation was kr87.8 Mil.
Total Current Assets was kr217.8 Mil.
Total Current Liabilities was kr205.1 Mil.
Net Income was -1.6 + -229.2 + -75.5 + -10.3 = kr-316.6 Mil.

Revenue was 136.9 + 130.5 + 143.2 + 112.9 = kr523.5 Mil.
Gross Profit was 59 + 61.1 + 63.8 + 53.6 = kr237.5 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(797.4 + 802.9 + 538.5 + 516.907 + 495) / 5 = kr630.1414 Mil.
Total Assets at the begining of last year (Mar24) was kr797.4 Mil.
Long-Term Debt & Capital Lease Obligation was kr57.5 Mil.
Total Current Assets was kr252.9 Mil.
Total Current Liabilities was kr259.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Boule Diagnostics AB's current Net Income (TTM) was -7.8. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Boule Diagnostics AB's current Cash Flow from Operations (TTM) was 20.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-7.8/495
=-0.01575758

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-316.6/797.4
=-0.39704038

Boule Diagnostics AB's return on assets of this year was -0.01575758. Boule Diagnostics AB's return on assets of last year was -0.39704038. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Boule Diagnostics AB's current Net Income (TTM) was -7.8. Boule Diagnostics AB's current Cash Flow from Operations (TTM) was 20.4. ==> 20.4 > -7.8 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=87.8/471.9914
=0.18602034

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=57.5/630.1414
=0.09124936

Boule Diagnostics AB's gearing of this year was 0.18602034. Boule Diagnostics AB's gearing of last year was 0.09124936. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=217.8/205.1
=1.06192101

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=252.9/259
=0.97644788

Boule Diagnostics AB's current ratio of this year was 1.06192101. Boule Diagnostics AB's current ratio of last year was 0.97644788. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Boule Diagnostics AB's number of shares in issue this year was 38.833. Boule Diagnostics AB's number of shares in issue last year was 38.148. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=202.4/478.4
=0.42307692

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=237.5/523.5
=0.45367717

Boule Diagnostics AB's gross margin of this year was 0.42307692. Boule Diagnostics AB's gross margin of last year was 0.45367717. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=478.4/495
=0.96646465

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=523.5/797.4
=0.65650865

Boule Diagnostics AB's asset turnover of this year was 0.96646465. Boule Diagnostics AB's asset turnover of last year was 0.65650865. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+1+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Boule Diagnostics AB has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Boule Diagnostics AB (CHIX:BOULS) has a Piotroski F-Score of 5 as of Jul. 14, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Boule Diagnostics AB and its competitors. This is near median its historical median of 5.00. Over the past decade, Boule Diagnostics AB's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Boule Diagnostics AB ranks #281 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 35%.
Is Boule Diagnostics AB's Piotroski F-Score too high?
Boule Diagnostics AB's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Boule Diagnostics AB's value of 5 is 0% at this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #281 out of 803 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Piotroski F-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #281 out of 803 companies for Piotroski F-Score. This puts Boule Diagnostics AB in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Boule Diagnostics AB's value of 5 is 0% at this benchmark. Historically, Boule Diagnostics AB's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Boule Diagnostics AB has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Piotroski F-Score of 5. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Medical Devices & Instruments industry median of 5.00. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Piotroski F-Score is 5 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.

Key valuation signals for CHIX:BOULS:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
  • GF Score™: 47/100 with 2 warning signs
  • Industry Position: 0% at the Medical Devices & Instruments median (#281 of 803)

No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score

Get the complete analysis for CHIX:BOULS

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.30
Price
kr49.42
GF Value